The DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.
Serum NFL discriminates Parkinson disease from atypical parkinsonisms
Open accessAbstract
Objective To investigate the diagnostic value of serum neurofilament light chain (NFL) in patients with clear signs of parkinsonism but whose specific diagnosis was yet uncertain. Methods Serum samples were collected from patients with clear signs of parkinsonism but with uncertain diagnosis at the inclusion. Clinical diagnoses of Parkinson disease (PD) and atypical parkinsonism disorders (APDs) were established after 3 years of follow-up and updated again after a maximum of 12 years in case longer follow-up data were available. Serum NFL was quantified by single molecule array in patients with PD (n = 55) and APD (n = 29, multiple system atrophy = 22, progressive supranuclear palsy = 7) and 53 nonneurologic controls. Results Serum NFL levels were elevated and differentiated the APD group (mean 23.8 ± 10.3 ng/L) from PD (mean 10.4 ± 4.9 ng/L) and controls (mean 11.5 ± 6.5 ng/L, p < 0.0001) with accuracy levels up to 91% (sensitivity = 86% and specificity = 85%). Serum NFL strongly correlated with CSF NFL levels (r = 0.72, p < 0.0001) in all groups and with age in PD (r = 0.78, p < 0.0001) and controls (r = 0.66, p < 0.0001). In our cohort, the probability of having APD was 76% (positive predictive value) and of having PD 92% (negative predictive value). Conclusion Serum NFL levels are markedly elevated in APD compared to PD and discriminate APDs from PD with high accuracy. Serum NFL may be a useful clinical biomarker to identify APD, even at stages when clinical symptoms are not yet conclusive. Classification of evidence This study provides Class II evidence that serum NFL levels accurately discriminate APDs from PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“We observed strong correlations between CSF and serum levels for NfL, as it has been previously reported [31, 88, 89].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
MDS clinical diagnostic criteria for Parkinson’s disease
Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., et al. (2015) · Movement Disorders · doi:10.1002/mds.26424 · Cited by 7,653
Self-citationSecond consensus statement on the diagnosis of multiple system atrophy
Gilman, S., Wenning, G. K., Low, P. A., Brooks, D. J., Mathias, C. J., Trojanowski, J. Q., Wood, N. W., Colosimo, C., Dürr, A., Fowler, C. J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000324625.00404.15 · Cited by 3,140
Litvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R. C., Goetz, C. G., Golbe, L. I., Grafman, J., Growdon, J. H., et al. (1996) · Neurology · doi:10.1212/wnl.47.1.1 · Cited by 2,538
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
Höglinger, G. U., Respondek, G., Stamelou, M., Kurz, C., Josephs, K. A., Lang, A. E., Mollenhauer, B., Müller, U., Nilsson, C., Whitwell, J. L., et al. (2017) · Movement Disorders · doi:10.1002/mds.26987 · Cited by 2,434
The Mini-Mental State Examination
Folstein, M. F. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790060110016 · Cited by 2,016
Scale for the assessment and rating of ataxia: Development of a new clinical scale
Schmitz-Hübsch, T., du Montcel, S. T., Baliko, L., Berciano, J., Boesch, S., Depondt, C., Giunti, P., Globas, C., Infante, J., Kang, J. S., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000219042.60538.92 · Cited by 1,967
Criteria for the diagnosis of corticobasal degeneration
Armstrong, M. J., Litvan, I., Lang, A. E., Bak, T. H., Bhatia, K. P., Borroni, B., Boxer, A. L., Dickson, D. W., Grossman, M., Hallett, M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e31827f0fd1 · Cited by 1,904
Parkinsonism: Onset, progression, and mortality
Hoehn, M., & Yahr, M. (2011) · Neurology · doi:10.1212/01.wnl.0000405146.06300.91 · Cited by 1,888
The Unified Parkinson's Disease Rating Scale (UPDRS): Status and recommendations
Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease (2003) · Movement Disorders · doi:10.1002/mds.10473 · Cited by 1,811
Trouillas, P., Takayanagi, T., Hallett, M., Currier, R. D., Subramony, S. H., Wessel, K., Bryer, A., Diener, H., Massaquoi, S. G., Gomez, C. M., et al. (1997) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(96)00231-6 · Cited by 1,281
The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service
Hughes, A. J., Daniel, S. E., Ben‐Shlomo, Y., & Lees, A. J. (2002) · Brain · doi:10.1093/brain/awf080 · Cited by 1,258
Hoehn, M. M. M., & Yahr, M. D. (1998) · Neurology · doi:10.1212/wnl.50.2.318 · Cited by 873
Kuhle, J., Barro, C., Andreasson, U., Derfuss, T., Lindberg, R., Sandelius, Å., Liman, V., Norgren, N., Blennow, K., & Zetterberg, H. (2016) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2015-1195 · Cited by 740
Neurofilament phosphoforms: Surrogate markers for axonal injury, degeneration and loss
Petzold, A. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.03.015 · Cited by 688
Alpha‐synuclein RT ‐Qu IC in the CSF of patients with alpha‐synucleinopathies
Fairfoul, G., McGuire, L. I., Pal, S., Ironside, J. W., Neumann, J., Christie, S., Joachim, C., Esiri, M., Evetts, S. G., Rolinski, M., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.338 · Cited by 608
Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis
Lu, C.-H., Macdonald-Wallis, C., Gray, E., Pearce, N., Petzold, A., Norgren, N., Giovannoni, G., Fratta, P., Sidle, K., Fish, M., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001642 · Cited by 563
Boeve, B. F., Lang, A. E., & Litvan, I. (2003) · Annals of Neurology · doi:10.1002/ana.10570 · Cited by 526
Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder
Hansson, O., Janelidze, S., Hall, S., Magdalinou, N., Lees, A. J., Andreasson, U., Norgren, N., Linder, J., Forsgren, L., Constantinescu, R., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000003680 · Cited by 506
Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases
Gaiottino, J., Norgren, N., Dobson, R., Topping, J. H., Nissim, A., Malaspina, A., Bestwick, J. P., Monsch, A. U., Regeniter, A., Lindberg, R. L. P., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075091 · Cited by 493
Hall, S., Öhrfelt, A., Constantinescu, R., Andreasson, U., Surova, Y., Bostrom, F., Nilsson, C., Widner, H., Decraemer, H., Nägga, K., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.1654 · Cited by 473
Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia
Rohrer, J. D., Woollacott, I., Dick, K. M., Brotherhood, E., Gordón, E., Fellows, A. D., Toombs, J., Druyeh, R., Cardoso, M. J., Sebastien Ourselin, A., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003154 · Cited by 450
Magdalinou, N. K., Paterson, R. W., Schott, J. M., Fox, N. C., Mummery, C. J., Blennow, K., Bhatia, K. P., Morris, H. R., Giunti, P., Warner, T. T., et al. (2015) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-309562 · Cited by 254
Neurofilaments as biomarkers in multiple sclerosis
Teunissen, C. E., & Khalil, M. (2012) · Multiple Sclerosis Journal · doi:10.1177/1352458512443092 · Cited by 236
Siller, N., Kühle, J., Muthuraman, M., Barro, C., Uphaus, T., Groppa, S., Kappos, L., Zipp, F., & Bittner, S. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458518765666 · Cited by 213
What Is the Accuracy of the Clinical Diagnosis of Multiple System Atrophy?
Litvan, I. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550200007003 · Cited by 211
Plasma neurofilament light chain predicts progression in progressive supranuclear palsy
Rojas, J. C., Karydas, A., Bang, J., Tsai, R. M., Blennow, K., Liman, V., Kramer, J. H., Rosen, H., Miller, B. L., Zetterberg, H., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.290 · Cited by 206
Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis
Feneberg, E., Oeckl, P., Steinacker, P., Verde, F., Barro, C., Damme, P. V., Gray, E., Großkreutz, J., Jardel, C., Kühle, J., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004761 · Cited by 203
Self-citationThe new definition and diagnostic criteria of Parkinson's disease
Postuma, R. B., Berg, D., Adler, C. H., Bloem, B. R., Chan, P., Deuschl, G., Gasser, T., Goetz, C. G., Halliday, G. M., Joseph, L., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00116-2 · Cited by 149
Self-citationCSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease
Abdo, W. F., Bloem, B. R., van Geel, W. J. A., Esselink, R. A. J., & Verbeek, M. M. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.03.010 · Cited by 130
Self-citationCSF α-synuclein does not differentiate between parkinsonian disorders
Aerts, M., Esselink, R. A. J., Abdo, W. F., Bloem, B. R., & Verbeek, M. M. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.12.001 · Cited by 126
Self-citationClinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum
Meeter, L. H. H., Vijverberg, E. G., Del Campo, M., Rozemuller, A. J. M., Donker Kaat, L., de Jong, F. J., van der Flier, W. M., Teunissen, C. E., van Swieten, J. C., & Pijnenburg, Y. A. L. (2018) · Neurology · doi:10.1212/wnl.0000000000005261 · Cited by 122
Enroth, S., Hallmans, G., Grankvist, K., & Gyllensten, U. B. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.08.038 · Cited by 102
CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls
Herbert, M. K., Eeftens, J. M., Aerts, M. B., Esselink, R. A. J., Bloem, B. R., Kuiperij, H. B., & Verbeek, M. M. (2013) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2013.09.003 · Cited by 84
Self-citationThompson, A. G. B., Luk, C. Y., Heslegrave, A., Zetterberg, H., Mead, S., Collinge, J., & Jackson, G. S. (2018) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-317793 · Cited by 84
CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders
Herbert, M. K., Aerts, M. B., Beenes, M., Norgren, N., Esselink, R. A. J., Bloem, B. R., Kuiperij, H. B., & Verbeek, M. M. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00091 · Cited by 79
Self-citationNeurofilament proteins in axonal regeneration and neurodegenerative diseases.
Wang, H., Wu, M., Zhan, C., Enyuan, M., Yang, M., Yang, X., & Li, Y. (2012) · Europe PMC (PubMed Central) · doi:10.3969/j.issn.1673-5374.2012.08.010 · Cited by 77
Wilke, C., Bender, F., Hayer, S. N., Brockmann, K., Schöls, L. J., Kühle, J., & Synofzik, M. (2018) · Journal of Neurology · doi:10.1007/s00415-018-8893-9 · Cited by 70
Neurofilament proteins in axonal regeneration and neurodegenerative diseases
Haitao, Wang, Min-fei, et al. (2012) · 中国神经再生研究：英文版 · Cited by 64
Constantinescu, R., Romer, M., Oakes, D., Rosengren, L., & Kieburtz, K. D. (2008) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.05.012 · Cited by 61
Ancillary investigations to diagnose parkinsonism: a prospective clinical study
Aerts, M., Esselink, R. A. J., Abdo, W. F., Meijer, F. J. A., Drost, G., Norgren, N., Janssen, M. J. R., Borm, G. F., Bloem, B. R., & Verbeek, M. M. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7568-4 · Cited by 34
Self-citationJabbari, E., Zetterberg, H., & Morris, H. R. (2017) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-315857 · Cited by 31
Willemse, E. A. J., van Uffelen, K. W. J., van der Flier, W. M., & Teunissen, C. E. (2017) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.03.005 · Cited by 26
Marques, T. M., van Rumund, A., Kuiperij, H. B., & Verbeek, M. M. (2017) · Handbook of clinical neurology · doi:10.1016/b978-0-12-804279-3.00007-1 · Cited by 6
Self-citation
Cited by
Sorted by citations
Bloem, B. R., Okun, M. S., & Klein, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00218-x · Cited by 3,920
Self-citationA multicentre validation study of the diagnostic value of plasma neurofilament light.
Ashton, N. J., Janelidze, S., Al Khleifat, A., Leuzy, A., van der Ende, E. L., Karikari, T. K., Benedet, A. L., Pascoal, T. A., Lleó, A., Parnetti, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23620-z · Cited by 545
Neurofilaments as biomarkers in neurological disorders — towards clinical application
Khalil, M., Teunissen, C. E., Lehmann, S., Otto, M., Piehl, F., Ziemssen, T., Bittner, S., Sormani, M. P., Gattringer, T., Abu‐Rumeileh, S., et al. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00955-x · Cited by 503
Self-citationBlood neurofilament light: a critical review of its application to neurologic disease
Barro, C., Chitnis, T., & Weiner, H. L. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51234 · Cited by 296
Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression
Mollenhauer, B., Dakna, M., Kruse, N., Galasko, D. R., Foroud, T., Zetterberg, H., Schade, S., Gera, R. G., Wang, W., Gao, F., et al. (2020) · Movement Disorders · doi:10.1002/mds.28206 · Cited by 201
Metadata
- Authors
- Marques, T. M., van Rumund, A., Oeckl, P., Kuiperij, H. B., Esselink, R. A. J., Bloem, B. R., Otto, M., & Verbeek, M. M.
- Affiliations
- Radboud University Nijmegen (NL)
- From the Department of Neurology (T.M.M., A.v.R., H.B.K., R.A.J.E., B.R.B., M.M.V.), Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen; Department of Laboratory Medicine (T.M.M., H.B.K., M.M.V.), Radboud University Medical Center, Nijmegen; Parkinson Center Nijmegen (T.M.M., A.v.R., R.A.J.E., B.R.B., M.M.V.), the Netherlands; and Department of Neurology (P.O., M.O.), Ulm University Hospital, Germany.
- ORCID
- Venue
- Neurology
- Published
- 2019-03-26
- Volume
- 92
- Issue
- 13
- Pages
- e1479-e1486
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2919112269
- Cited by
- 153
- References
- 45
- Citations by year
- 2026: 12 · 2025: 21 · 2024: 21 · 2023: 23 · 2022: 22 · 2021: 31 · 2020: 18 · 2019: 5
- FWCI
- 12.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- neurofilament light chain, serum biomarkers, Parkinson's disease, atypical parkinsonism, multiple system atrophy, progressive supranuclear palsy, differential diagnosis, diagnostic accuracy
- MeSH terms
- Aged, Diagnosis, Differential, Female, Humans, Male, Middle Aged, Parkinson Disease, Sensitivity and Specificity, Supranuclear Palsy, Progressive, Case-Control Studies, Neurofilament Proteins, Multiple System Atrophy, Parkinsonian Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
